Quantcast

Latest Trovagene Inc. Stories

2014-07-01 08:29:52

Strengthens balance sheet to fund clinical programs, commercialization efforts, and continued expansion of oncogene mutation portfolio for cancer monitoring SAN DIEGO, July 1, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced that it has secured an unrestricted debt facility in the amount of $15 million from Silicon Valley Bank and Oxford Finance LLC. The additional capital will be used to support ongoing development and commercialization activities for the...

2014-06-30 08:30:41

SAN DIEGO and CHICAGO, June 30, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) have entered into a strategic partnership to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice....

2014-06-16 08:28:29

Company continues to engage leading cancer treatment centers to investigate non-invasive methods of cancer mutation detection in order to advance patient care SAN DIEGO, June 16, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time...

2014-06-02 12:29:45

Clinical Study Results Published in 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology CHICAGO, June 2, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), today announced that data from a study published in the 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology, demonstrates that oncogene mutation load in urinary cell-free DNA, as determined using the company's precision cancer monitoring technology, is significantly correlated with treatment response....

2014-05-28 16:27:15

SAN DIEGO, May 28, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Financial Officer Stephen Zaniboni is scheduled to present a corporate overview at the Jefferies 2014 Global Healthcare Conference. http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO Trovagene is scheduled to present at the Jefferies 2014 Global Healthcare Conference at the Grand Hyatt in New York, NY on Monday , June 2, 2014 at...

2014-05-28 08:27:55

Non-invasive detection and monitoring of actionable oncogene mutation in Erdheim-Chester disease serves as a model case for clinical utility SAN DIEGO, May 28, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that the multi-disciplinary clinical consensus guidelines for Erdheim-Chester disease (ECD), recently published online in the journal Blood, reference the ability of the Company's precision cancer monitoring...

2014-05-20 08:29:42

Data demonstrate utility of non-invasive testing using urinary cell-free DNA to determine oncogene mutation status for therapy selection SAN DIEGO, May 20, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that data published from ongoing clinical validation studies demonstrate that the company's precision cancer monitoring technology is suitable to non-invasively determine oncogene mutation status in patients with...

2014-05-14 16:29:04

SAN DIEGO, May 14, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that data from a study of its precision cancer monitoring technology, conducted by MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, will be presented during a poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). An additional abstract, submitted by Filip Janku, M.D., Ph.D., of The...

2014-05-12 16:28:41

SAN DIEGO, May 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO "Our focus is to demonstrate the benefit of our precision cancer monitoring platform through research collaborations and expansion of our product offerings," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "In the first...

2014-05-05 16:27:05

SAN DIEGO, May 5, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter ended March 31, 2014 on Monday, May 12, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time). http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO Trovagene's management team will host a conference call on Monday, May 12, 2014 at 5:00 p.m. Eastern Daylight Time (2:00 p.m....


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.